All in favor say ‘eye’

Bausch & Lomb's Optura (besifloxacin ophthalmic suspension) receives unanimous support Dec. 5 for treatment of bacterial conjunctivitis. Members of FDA's Dermatologic and Ophthalmic Drugs Advisory Committee added no hesitations or qualifications to their 9-0 vote that besifloxacin's benefits outweigh its risks, agreeing with FDA's conclusions that the sponsor conducted three adequate and well-controlled trials supporting the drug's efficacy

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet